In 2024, the systemic hormonal preparations market (excluding sex hormones and insulins) in Canada is projected at $736.5 million, growing steadily to $846.5 million by 2028. From 2024 to 2028, we observe incremental year-on-year growth, indicating a stable market with annual increases maintaining a consistent pattern. Based on the given data, the compound annual growth rate (CAGR) is expected to reflect a healthy average annual increase over this period.
Looking ahead, potential drivers for growth include advancements in hormonal therapy, increased prevalence of conditions treated by these medications, and innovations in drug delivery systems. Monitoring regulatory changes and healthcare policies will be vital as they could significantly impact market dynamics.
